DVA — DaVita Inc.

DaVita (DVA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Adjusted Operating Income: $586 million; Full Year Adjusted Operating Income: $2.094 billion.
• Q4 Adjusted Earnings Per Share (EPS): $3.40; Full Year Adjusted EPS: $10.78.
• Free Cash Flow: $309 million in Q4, totaling over $1 billion for the year.
• U.S. Dialysis Treatments: Declined by 1.1% for the full year; Q4 saw a 20 basis point decline versus Q4 2024.
• Revenue Per Treatment (RPT): Increased by approximately $12 sequentially in Q4, with a full-year increase of 4.7% to about $410.

2. Strategic Updates and Business Highlights

• Integrated Kidney Care (IKC): Achieved its first profitable year, slightly ahead of schedule, with a full-year adjusted operating income of $22 million. IKC patients showed significantly better clinical outcomes compared to the broader dialysis population.
• Clinical Initiatives: Focus on vaccination rates, GLP-1 drug adoption, and new dialysis technologies aimed at improving patient outcomes and reducing hospitalizations.
• Partnership with Elara Caring: A strategic investment of approximately $200 million to enhance home care services for patients with end-stage kidney disease (ESKD).
• International Business: Generated $114 million in adjusted operating income, reflecting strong organic growth and successful integration of recent acquisitions.

3. Forward Guidance and Outlook

• 2026 Adjusted Operating Income Guidance: Expected in the range of $2.085 billion to $2.235 billion (3.2% growth at midpoint).
• Adjusted EPS Guidance for 2026: Projected between $13.60 and $15.00, indicating a 33% growth at the midpoint.
• Free Cash Flow Guidance: Anticipated between $1 billion and $1.25 billion.
• Treatment Volume Outlook: Expected to be flat compared to 2025, with a focus on improving clinical outcomes to drive future growth.

4. Bad News, Challenges, or Points of Concern

• Treatment Growth Pressure: Continued pressure on treatment growth due to elevated mortality rates and the expiration of enhanced premium tax credits, which is expected to create a $40 million headwind in 2026.
• Patient Care Costs: Increased by approximately $6 sequentially in Q4, driven by seasonal health benefit costs and supply costs, with a full-year increase of 5.9%.
• Cyber Incident Impact: The company faced challenges in 2025 due to a cyber incident, which affected operations and financial performance.

5. Notable Q&A Insights

• Volume Growth Confidence: CEO Javier Rodriguez emphasized that achieving over 2% volume growth hinges on improving mortality rates and implementing clinical initiatives, with expected benefits materializing over the next few years.
• ACA Headwinds: The anticipated $40 million headwind from the expiration of enhanced premium tax credits is expected to be offset by the elimination of the cyber incident's financial impact.
• IKC Performance Drivers: The outperformance in IKC was attributed to better shared savings and effective management of patient care, although future growth in this segment is expected to slow as the business matures.
• Vaccination Rates: Current flu vaccination rates are at 80%, below the historical benchmark of over 90%, indicating room for improvement in patient care initiatives.

Overall, DaVita's Q4 2025 results reflect a resilient business model with a focus on clinical excellence and strategic growth initiatives, despite facing headwinds in treatment growth and rising costs.